Pancreatic Cancer Research

ResearcherYamaguchi UniversityNo recent work listed

Masaaki Oka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5073526618, A5102135875. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers

Papers 10

  1. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Co-author DOI 10.1097/mpa.0000000000000880↗
  2. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  3. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  4. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Co-author DOI 10.1111/cas.13061↗
  5. Cofilin-phosphatase slingshot-1L (SSH1L) is over-expressed in pancreatic cancer (PC) and contributes to tumor cell migration. Co-author DOI 10.1016/j.canlet.2015.02.015↗
  6. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates gr… Co-author DOI 10.1080/15384047.2014.1002357↗
  7. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Last author DOI 10.1097/cji.0000000000000012↗
  8. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Last author DOI 10.1186/1479-5876-12-175↗
  9. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Last author DOI 10.3892/ijo.2014.2603↗
  10. Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Co-author DOI 10.3892/or.2012.2004↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshitaro Shindo · 7 shared papers, 2014–2017 · strength 0.31
  2. Tomio Ueno · 7 shared papers, 2012–2017 · strength 0.30
  3. Nobuaki Suzuki · 7 shared papers, 2012–2017 · strength 0.29
  4. Hiroto Matsui · 6 shared papers, 2014–2017 · strength 0.27
  5. Hiroaki Nagano · 3 shared papers, 2016–2017 · strength 0.15
  6. Ryouichi Tsunedomi · 3 shared papers, 2014–2016 · strength 0.12
  7. Satoshi Matsukuma · 2 shared papers, 2016–2017 · strength 0.10
  8. Haruo Iguchi · 2 shared papers, 2017 · strength 0.09
  9. Takashi Hatori · 2 shared papers, 2017 · strength 0.09
  10. Tetsuya Ikemoto · 2 shared papers, 2017 · strength 0.09
  11. Yuzo Umeda · 2 shared papers, 2017 · strength 0.09
  12. Mitsuo Shimada · 2 shared papers, 2017 · strength 0.09
  13. Yusuke Nakamura · 2 shared papers, 2017 · strength 0.09
  14. Toshiyoshi Fujiwara · 2 shared papers, 2017 · strength 0.09
  15. Kazuyuki Nakamura · 2 shared papers, 2012–2015 · strength 0.08
  16. Yufeng Wang · 2 shared papers, 2012–2015 · strength 0.08
  17. Yasuhiro Kuramitsu · 2 shared papers, 2012–2015 · strength 0.08
  18. Yusaku Watanabe · 2 shared papers, 2014–2016 · strength 0.08
  19. Byron Baron · 1 shared paper, 2015 · strength 0.05
  20. Yoshihiko Maehara · 1 shared paper, 2015 · strength 0.05
  21. Hiroaki Nagano · 1 shared paper, 2017 · strength 0.05
  22. Kosei Hirakawa · 1 shared paper, 2017 · strength 0.05
  23. Sonshin Takao · 1 shared paper, 2015 · strength 0.05
  24. Susumu Ishiguro · 1 shared paper, 2015 · strength 0.05
  25. Masaaki Tamura · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.